



DOI: 10.5281/zenodo.4070120

UDC: 617.713-089.843:611.013.83



# EFFICIENCY OF AMNIOTIC MEMBRANE TRANSPLANTATION IN THE MANAGEMENT OF LIMBAL STEM CELL DEFICIENCY

**Vitalie Procopciuc**<sup>1,4</sup>, PhD student, **Viorica Mihaluța**<sup>2</sup>, PhD student, **Olga Ignatov**<sup>3,4</sup>, PhD student, **Valeriu Cușnir**<sup>1</sup>, PhD in Medical Sciences, professor, **Viorel Nacu**<sup>4</sup>, PhD in Medical Sciences, professor

<sup>1</sup> State University of Medicine and Pharmacy "Nicolae Testemițanu", Department of Ophthalmology-Optometry, Chișinău, Republic of Moldova

<sup>2</sup> State University of Medicine and Pharmacy "Nicolae Testemițanu", Department of Surgery no. 2, Chișinău, Republic of Moldova

<sup>3</sup> State University of Medicine and Pharmacy "Nicolae Testemițanu", Department of Medical Rehabilitation, Physical Medicine and Manual Therapy, Chișinău, Republic of Moldova

<sup>4</sup> Laboratory of Tissue Engineering and Cell Cultures, Chișinău, Republic of Moldova

## Abstract

**Objectives.** This paper aims to examine the efficacy, safety, and long term outcomes of amniotic membrane transplantation for corneal surface reconstruction, in cases of limbal stem cell deficiency.

**Material and methods.** A systematic literature search was performed on PubMed, for papers published up to February 2020, using the following combined search terms: "limbal stem cell deficiency", "amniotic membrane", "limbal transplant". Only clinical trials with human subjects were selected for analysis. We collected the data on amniotic membrane properties and mechanisms of action, processing, preservation and transplantation techniques, and clinical outcomes of different treatment methods.

**Results.** The surgical approach for treating limbal stem cell deficiency depends on the extent of the disease. Isolated amniotic membrane transplantation appears to have a limited beneficial effect on limbal stem cells, whereas amniotic membrane transplantation, combined with certain types of limbal stem cell transplantation, provides long-term biological and mechanical support for the donor tissue explants. Combined with simple limbal epithelial transplantation, the amniotic membrane has shown excellent results in the surgical management of limbal stem cell deficiency.

**Conclusions.** Preliminary results of amniotic membrane use in limbal transplantation show quite satisfactory data, but the lack of high-level randomized controlled studies makes it difficult to assess the comparative efficacy of amniotic membrane transplantation in limbal stem cell deficiency surgical management.

**Keywords:** amniotic membrane, cornea, limbal stem cell deficiency, limbal graft

## Introduction

Limbal stem cells (LSC) have the function of regenerating corneal epithelial cells, as well as maintaining the integrity of the corneal epithelium [1]. Various ocular pathologies can affect the limbal region, causing LSC dysfunction. Limbal stem cell deficiency (LSCD) is a condition characterized by a number of pathological signs: delayed or incomplete regeneration of epithelial lesions, recurrent epithelial erosions, scarring and stromal opacity, prolonged corneal edema after cataract surgery, rejection of the corneal graft, etc. [2] Among the causes of LSCD are pathologies such as: chemical and thermal burns, severe microbial infections, chronic cicatricial inflammation (Stevens-Johnson syndrome and bullous pemphigoid), incorrect wearing of contact lenses, trauma, etc. [3]

LSCD treatment is not an easy task, and attempts to restore the integrity and functionality of LSC are often in vain. It should be noted that corneal transplantation cannot treat LSCD and usually fails after surgery. Therefore, LSCD management requires a complex approach and, most of the time, the combination of several treatment methods. Medical therapy

has a limited success rate and is only appropriate in mild cases [4]. All cases of moderate to severe LSCD require surgical management. The main directions of LSCD surgical treatment are: direct limbal tissue transplantation and ex vivo/in vivo expanded LSC transplantation [5]. The amniotic membrane (AM), used alone or as a substrate for LSC, can be incorporated into LSC transplantation in almost all surgical approaches. This review aims to investigate the role of AM and its effectiveness in the surgical management of LSCD.

## Material and methods

In this paper, we reviewed the literature in order to analyze current data on applications of amniotic membrane in surgical management of limbal stem cell deficiency and summarized the results of different surgical approaches. A systematic literature search was performed on PubMed for papers published up to February 2020, using the following combined search terms: "limbal stem cell deficiency", "amniotic membrane", "limbal transplant". Only clinical trials with human subjects were selected for analysis. We collected the data on amniotic

membrane properties and mechanisms of action, processing, preservation and transplantation techniques, and clinical outcomes of different treatment methods.

## Results

### A. Structure, properties and mechanisms of action of the amniotic membrane

AM is a biological material of the human placenta, constituting the inner wall of fetal membranes [6]. It has a fetal part - the chorion, and a maternal component - the decidua. Histologically, it consists of a monolayered epithelium, rich in collagen basement membrane, and stroma. Amniotic epithelial cells have qualities that make them a very good source of stem cells. Thus, studies have shown that these cells have "stem-like" characteristics, as they express surface cell markers associated with embryonic stem cells (such as SSEA 3 and SSEA 4), TRA 1-60 and TRA 1-81. It should also be noted that these cells express transcription factors specific to pluripotent stem cells, such as Oct-4 ("octamer binding transcription factor"), which suggests the pluripotent ability to differentiate [7].

The amniotic membrane transplantation (AMT) can be used either as a graft, to replace damaged tissue on the eye surface, or as a tissue patch to prevent the spread of inflammation. The mechanisms of action are: anti-inflammatory, antiangiogenic, facilitator of epithelialization. Also, through the biological similarity between the conjunctiva and the amniotic basement membrane, the latter can be a matrix for the development of epithelial cells, supporting their differentiation and nutrition and prolonging their lifespan. The AM functions as a substrate for stem cell expansion, with implications in the treatment of LSCD of various etiologies and in facilitating the epithelialization of severe corneal ulcers with epithelial and stromal destruction [8].

Restoring ocular homeostasis after a severe disease is a challenge, due to its complexity, which requires both reconstructive surgery and the modulation of cellular mechanisms of inflammation, scarring and tissue regeneration in vitro.

AM has many beneficial properties:

- anti-inflammatory: AM produces natural inhibitors of metalloproteinases and suppresses the pro-inflammatory cytokines IL1-alpha and IL1-beta [9]; AM, also, induces apoptosis of inflammatory cells in chemical burns of the ocular surface [10].

- antimicrobial: AM produces beta defensins and proteinase inhibitors, adhering tightly to the damaged surface and constituting a barrier against the external environment [11];

- antifibrotic and antiadhesive: AM secretes the tissue inhibitor of metalloproteinase, which inhibits protease activity, with the reduction of tissue fibrosis; also, by inhibiting TGF beta, the inactivation of fibroblasts is obtained, which prevents the formation of adhesions between the damaged tissue surfaces [12];

- immunological inertia and low level of antigenicity: these translate into very low expression of histocompatibility antigens HLA, B, CDR, beta-2-microglobulin and unique surface and biochemical properties of placental membranes, which do not express the MHC II class of histocompatibility antigens [13];

- analgesic: rapid pain reduction, by effectively covering the nerve endings [14];

- antiangiogenic: AM epithelial cells express antiangiogenic molecules, such as thrombospondin-1 and endostatin; metalloproteinase inhibitors have also been isolated in amniotic

epithelial cells: type 1, 2, 3, 4; at the level of the amniotic basement membrane was identified the pigment epithelial derived factor (PEDF), with strong anti-angiogenic properties; recent studies have shown that the antiangiogenic effect of the AM may be influenced by the presence of inflammation and the type of pathology [9, 15];

- promoter of cell differentiation and deionization, through the content of type IV, V and VII collagen [16];

- favoring epithelialization, through several mechanisms: the amniotic basement membrane represents the support for the growth of epithelial cells and maintaining their functionality; at the level of AM, the migration and differentiation of epithelial cells is facilitated; collagen-rich amniotic basement membrane is a very good substrate for re-epithelialization; at the level of AM are expressed several growth factors: KGF (keratinocyte growth factor – present in the epithelialization phase of wound healing, when keratinocytes cover the wound); bFGF (basic fibroblast growth factor – involved in angiogenesis, wound healing, embryo development); HGF (hepatocyte growth factor – that regulates cell growth, motility and morphogenesis); TGF-beta (transforming growth factor beta – that controls cell proliferation and differentiation) [16, 17].

### B. Limbal stem cells - anatomy, physiology and pathology

The ocular surface is an anatomical assembly, consisting of three contiguous structures: conjunctiva, limbus and cornea. The limbus is the anatomical barrier between the transparent and avascular cornea and the sclera, covered by the richly vascularized conjunctiva. It represents the transition area between the corneal epithelium and the epithelium of the bulbar conjunctiva. Basically, there are three ways in which the limbus can be described: anatomical, histological and surgical [18]. The limbal epithelium is a transitional epithelium between two biologically different areas: the conjunctival area, vascularized and rich in lymphoid elements, and the corneal, avascular and richly innervated area [19]. At this level, the epithelium and conjunctival stroma are organized into papillary formations, similar to dermal papillae, radially oriented and called "Vogt palisades" (0.5 mm x 2-4 mm). Fine blood vessels, nerves, and lymphatic vessels pass through the palisades, inside which are the corneal stem cells [20].

The regeneration of the corneal epithelium depends on these stem cells [14]. The term was introduced by Till and McCulloch [15], and defines cells with self-regenerative and differentiation potential in all cell types [16]. The limbal stem cell theory has crucially changed the therapeutic approach to ocular surface pathologies in humans, allowing the destruction of the ocular surface of various etiologies (inflammation, burns, trauma) to be treated by auto- or allografts of limbal stem cells, all on AM support [17]. Limbal stem cells prevent the invasion of the corneal epithelium by the conjunctival one, ensuring the transparency of the cornea. The corneal epithelium contains keratin 3 and 12 (K3/K12) and the cells of the conjunctival epithelium contain keratin 7 and keratin 19 (K7/K19) [17]. Specific cellular markers can assess the degree of cell differentiation, and these markers can be used to demonstrate limbal stem cell failure syndrome. Detection of MUC5AC transcription in corneal epithelial cells, by polymerase chain reaction, is a method of molecular diagnosis of limbal stem cell failure. In the case of destruction of all limbal stem cells, the conjunctival epithelium would replace the corneal one, the cornea becoming opaque.

This demonstrates that the limbus is essentially involved in regulating the differentiation of the corneal epithelium [19]. Regulatory dysfunction of cell differentiation in limbal stem cell insufficiency leads, either to corneal epithelial metaplasia (in which case the corneal epithelium can "conjunctivalize"), or to its dysplasia with carcinogenesis [21].

Conjunctiva and cornea respond very differently to the aggressions to which they are exposed (mechanical, microbial, toxic): the conjunctiva is immunologically hyperactive, whereas the cornea benefits from the so-called immune privilege and inhibition of inflammatory reactions, in order to preserve its transparency. Immunological reactions, at the ocular surface level, are performed through a complex network of inflammatory cells, cytokines and chemokines. There is a dual unitary system: innate and acquired, which works complementarily and/or intricately [22].

LSCD is a complex ophthalmic disorder that accompanies a number of congenital or acquired pathological conditions, resulting in the total or partial dysfunction of these cells. The clinical resonance of LSCD derives from this dysfunction, with the most severe effects on the integrity of the cornea and the entire ocular surface [14, 16]. The etiology of LSCD is varied; from chemical, thermal and mechanical aggressions of the limbus (burns, multiple surgeries, antimetabolic agents, dry eye syndrome, etc.), to infections (recurrent ulcer), chronic inflammation, neoplasms and destruction of the corneal matrix (neurotrophic keratitis) [23]. Chronic corneal ulcer and corneal neovascularization are the main complications of LSCD.

AMT acts in LSCD through several mechanisms:

- a) prolongs the lifespan and maintains the clonogenicity of the progenitor epithelial cells;
- b) favors the differentiation of epithelial cells, avoiding the differentiation into goblet cells;
- c) favors the differentiation of goblet cells in the presence of conjunctival fibroblasts;
- d) inhibits inflammatory cells with antiprotease activity;
- e) suppresses the molecular signaling system of TGF-beta and differentiation of normal fibroblasts [24].

The AM is a tissue, unique in its biochemistry. In terms of lack of immunogenicity – it is the ideal transplant; in terms of the richness of growth factors and cytokines – it is a tissue that facilitates healing; in terms of harvesting and transplantation technique – it is affordable. All these qualities argue for the use of the AM in severe pathology of the ocular surface.

### C. Sampling, processing and preserving the amniotic membrane

The potential donor is assessed before birth and after expressing full consent. AM should be obtained aseptically, after cesarean section, in a full-term pregnancy. It is excluded to take the AM after vaginal birth, because it can be contaminated with the saprophytic flora of the birthways. Diseases of the urogenital tract, other diseases of the donor or fetus, that may present a risk to the recipient, include: significant local bacterial, viral, parasitic or fungal infections of the genital tract, especially chorioamnionitis; (known) malformations of the newborn; premature rupture of membranes; endometritis; meconium ileus; tuberculosis, syphilis, HIV/AIDS; viral hepatitis B, C, D [25].

Taken samples are processed to facilitate longer storage periods until transplantation. Fetal membranes should be

rinsed several times, the amnion and the chorion should be mechanically separated, and blood residues should be removed. The amnion must be placed separately on a suitable support membrane (e.g. nitrocellulose), where it must be divided into smaller pieces (50x30 mm) [26].

There are several methods for preparing and preserving AM.

#### *Cryopreservation*

The AM can be cryopreserved in a cryoprotective medium (10% dimethyl sulfoxide), using a suitable container (bags or cryotubes) and transferred to liquid nitrogen tanks (vapor phase, below -130°C). However, when AM is stored in a sterile glycerol medium (and nutrient medium), the storage temperature is usually below -75°C [27].

#### *Thermally dried AM*

The tissue is dried overnight in an oven at 40°C ± 2°C, and then sterilized with radiation. The membrane loses many of its biological properties due to the high temperature, so the AM kept this way is usually employed as a biological dressing for the management of burns.

#### *Preservation of the AM with dry air*

After the AM is separated and washed under sterile conditions, it is dried overnight with dry air in a laminar flow hood. It can then be packaged and sterilized with radiation. Although high temperatures are not applied using this method, some properties of the amnion are lost or altered, due to dehydration. AM prepared this way can be used for dressings. Air-dried AM must be transported at room temperature [28].

#### *Lyophilized AM*

AM can be cut into pieces and quickly frozen at -50°C to -80°C. It is then dried under vacuum, using a freeze-drying device. The water from the tissue is extracted by sublimation, until a final water content of 5-10% is reached. The tissue can then be packaged and sterilized by irradiation. This type of preparation induces minimal changes in the properties of the amniotic membrane, and the product can be stored at room temperature. Freeze-dried AM should be transported at room temperature. AM preserved by this method is mainly used for wound management [29].

#### *Preservation in cold glycerol*

Glycerol has long been used as a cryoprotective agent. Due to its high osmotic potential, it can extract interstitial water from AM. 80% glycerol is normally used to store the AM. Under such conditions, AM can be stored at 2-8°C for a long period, although it loses some of its biological properties. AM kept this way is used as a biological dressing for burns.

#### *AM soaked in antibiotics*

After separation, the AM is placed overnight in a solution consisting of various types of broad-spectrum antibiotics, an antifungal agent and a nutrient medium. It is then frozen at -80°C. The resulting AM is convenient for the treatment of infected wounds in combustion, by ensuring an adequate concentration of antibiotics on the wound surface [30].

### D. Principles and surgical methods of amniotic membrane implantation

#### *Determination of AM orientation on the ocular surface*

The indication for which the AM is used and the desired final effect, determine the orientation with which it is applied to the ocular surface. Histopathological analysis showed that, after the application of AM, repopulation of the ocular surface by the host epithelium (e.g. the host corneal or conjunctival epithelium)

occurs preferentially on the basement membrane side of the epithelium [31], although, Seitz et al. [32] demonstrated that corneal epithelial cells also have the ability to grow on the stromal side of the membrane. When the membrane is used to secure the conjunctival or corneal cells with a substrate on which they could grow, AM is applied with the epithelial/basal face up. On the other hand, the stromal matrix of AM has the ability to capture inflammatory cells and induce their apoptosis, thus regulating the inflammatory response [33]. Thereby, in the presence of acute inflammation, the membrane can be used to protect the ocular surface from the harmful effects of cells and proinflammatory mediators. In this case AM is applied with the epithelial face down, so that the stromal face is oriented towards the eyelids.

The AM, provided on the nitrocellulose filter paper, is usually oriented with the epithelial side up, with the stromal face in direct contact with the paper. The stromal surface can be identified by the presence of vitreous-like strands that can be lifted with a sponge or fine forceps. Depending on the indication for which it is used, there are three surgical techniques by which AM can be applied to the ocular surface.

#### *Inlay technique ("graft")*

In this technique, AM is intended to act as a substrate for epithelial cell growth. The AM is placed with the epithelial/basement membrane facing up and cut to fit the size of the underlying epithelial or stromal defect. It is usually secured to the cornea with a 10-0 nylon suture or to the episclera and conjunctiva, using a 9-0 or 10-0 vicryl thread. It is preferable to keep the epithelium up in this technique, as the amniotic basement membrane acts as an excellent substrate for the growth of progenitor epithelial cells, by prolonging their lifespan, maintaining clonogenicity and preventing apoptosis [34]. Approximately 1-2 mm of the surrounding epithelium of the host cornea is debrided. This ensures that the regenerated epithelium grows over the basement membrane of the AM and, therefore, the amniotic stroma becomes embedded in the host tissue (graft). Depending on the depth of the underlying defect, this technique can use a single layer of AM (single-layer graft) or several (multi-layer graft). In the second case, several layers of unsutured AM are placed in the ulcer crater, over which a last layer of AM sutured to the edges of the ulcer is placed, after a prior deepithelization and debridement of the area around the corneal defect. The epithelium is to grow over the top layer of this multilayer graft. Layering can be done either by cutting the AM into several pieces and placing them on top of each other, or using a larger piece of folded AM.

#### *Overlay technique ("patch")*

In this case, a fragment of AM, larger than the underlying

defect, is sutured to the ocular surface so that the host epithelium is completely covered by the membrane. The AM is secured to the perilymbal conjunctiva using 9-0 vicryl or 10-0 nylon suture. The membrane can be placed with both the epithelial side and the stromal side up, as the host epithelium is to regenerate under the membrane, which, in this case, acts as a therapeutic contact lens or a biological bandage, designed to protect the new and fragile epithelium from the forces of friction generated by eyelid movements. In this situation, the AM either decomposes, or is removed after a certain period.

#### *Combined technique ("sandwich")*

In this technique, two or more layers of AM are used - the inner layer or layers serving as a graft and the larger outer layer serving as a patch. Also, known as the "sandwich" technique, this method involves combining single-layer or multi-layer graft techniques ("inlay") with biological patching ("overlay"). In this case, the epithelium is expected to grow under the bandage, but over the graft.

The availability of fibrin glue for ophthalmic use has, in many cases, replaced the application of sutures, and the AM can be adhered to the ocular surface using recombinant fibrin glue. This reduces the time of intervention, but also increases patient comfort [36, 45].

### **E. Limbal stem cell deficiency - surgical treatment using amniotic membrane**

#### 1. Isolated AMT

AMT can be used in the treatment of chemical burns and thermal injuries, due to its properties of epithelium healing [35]. It also seems to be beneficial in managing the Stevens-Johnson Syndrome, thanks to its anti-inflammation properties [36]. Here, the AM is acting as a temporary patch, protecting the ocular surface, promoting epithelial healing and preventing cicatricial sequelae. That being said, controlled clinical trials failed to show any definitive long-term benefits of AMT alone, in comparison to medical therapy, when it comes to visual outcome, ocular surface integrity and corneal vascularization [37]. AMT has also been used for treating partial LSCD [38]. In this case, as histological findings show, the effect of AM is believed to reside in its biological properties rather than mechanical ones [39].

#### *Surgical technique*

After fibrovascular pannus was surgically debrided and the inflamed tissue was removed, AM was taken out from the container with a suitable storage environment and placed over the freshly denuded cornea and limbus. In most studies, AM was placed with the epithelium facing up [40, 41, 42]. AM was secured either to the cornea, with 10-0 nylon sutures [40, 43], or to the perilymbal conjunctiva using 9-0 Vicryl sutures [24,

**Table 1**

*Outcomes of AMT alone, in patients with LSCD*

Year of publication	Author	No of eyes	Mean age	Re-epithelialization (weeks)	Stable cornea (%)	VA improvement (%)	Follow-up (months)
2015	Chugh JP <sup>[41]</sup>	30	48.9±16.3	2	-	55	6
2013	Konomi K <sup>[38]</sup>	16	57.4±16.4	1.5	31.2	31	52.3±26.3
2008	Kheirkhah A <sup>[48]</sup>	11	32.4±18.4	2.5	72.7	-	14.2±7.7
2005	Lopez-Garcia JS <sup>[47]</sup>	14	37	2	-	60	24
2005	Ivekovic R <sup>[42]</sup>	5	31.6±12.3	3	60	80	18±4.3
2003	Gomes JA <sup>[46]</sup>	4	34.5±26.3	3	-	-	17.5±5.1
2001	Anderson DF <sup>[40]</sup>	17	42.3±4.6	2.5	58.8	29	25.8±2.5

44]. In the latest studies, there were reports that fibrin glue can prevent suture-related complications [36, 45].

*Results*

We selected 7 studies [38, 40-42, 46-48] that reported results of isolated AMT in the treatment of partial LSCD (Table 1). Complete corneal and conjunctival re-epithelialization usually occurred in 1.5-3 weeks [38, 40, 46]. Stable epithelial surface was maintained during a period of 12-25 months after surgery [40, 42, 47]. Visual acuity (VA) has improved in 29-80% of operated eyes [38, 40-42, 46, 48]. Nonetheless, the success rate of AMT alone, in patients with LSCD, was only 31% at over a 50 months follow-up period [38].

**2. Transplantation of limbal tissues combined with AM**

There are three methods of direct limbal tissues transplantation: conjunctival limbal autograft transplantation (CLAU), conjunctival limbal allograft transplantation (CLAL) and keratolimbal allograft transplantation (KLAL). Because there is no consistent data on KLAL, we didn't include these studies into the analysis. Instead, we focused mainly on the techniques, indications and effectiveness of CLAU and CLAL combined with AMT.

*Surgical technique*

**Inlay technique:** In this case, AM was placed on the ocular surface and sutured, then the limbal graft was secured to the recipient limbal area [24, 28]. This way, AM is believed to alleviate inflammation and scarring after surgery. Additionally, the combination of AMT may improve the regeneration of LSCs

[49] and decrease the risk of induced LSCD in the donor's eye.

**Overlay technique:** After the application of limbal tissues, AM was placed as a temporary patch over the grafts, covering the entire ocular surface [50]. In some cases, AM was placed first under and then over the transplanted limbal grafts – the so called "sandwich" technique [49]. Here, the AM plays the role of a contact lens, providing mechanical protection and relieving postoperative pain and discomfort.

*Results*

A total of 15 studies [42, 46, 51-63] were selected for the analysis of the outcome of CLAU or CLAL (Table 2). The follow-up period in these studies was at least 12 months. One study [42] compared the re-epithelialization times in three distinct groups: after AMT (24 days), CLAU (14 days), and CLAU plus AMT (15 days). No notable difference was reported between CLAU and CLAU combined with AMT, but there was a greater re-epithelialization time when AMT was used alone. Another study [51] showed that, even though the graft success rate was somewhat similar between the tested groups regardless of the use of AMT, the re-epithelialization was considerably slower in the group with AMT. However, the lack of sufficient comparative studies and the difference between study designs and population structure means that there is insufficient data to demonstrate the effectiveness of combining AMT with CLAU or CLAL [46, 52-55, 62]. Nonetheless, AMT is being actively used as a common procedure in direct limbal tissue transplantation for its healing properties and to increase graft survival rate [56, 57].

**Table 2**  
*Outcomes of AMT+CLAU/CLAL in patients with LSCD*

Year of publication	Author	No of eyes	Mean age	Re-epithelialization (weeks)	Stable cornea (%)	VA improvement (%)	Follow-up (months)
2017	Arora R [55]	10	18±8	2.5	90	33	6
2015	Moreira PB [58]	28	40.3	4	-	-	24.8
2014	Barreiro TP [51]	15	36.3	2	73.3	66	19.7±5.6
2012	Baradaran-Rafii [56]	34	27.3±9.4	3.5	-	58	17.2±6.3
2012	Eberwein P [59]	20	44	1.5	-	-	22.4
2011	Han ES [60]	24	39.4±17.4	4	66.6	62	47.3±22
2010	Miri A [57]	27	-	2	-	48	38±35.9
2008	Scooco C [54]	39	33.6±18.9	1.5	69.2	-	48.7±30.6
2008	Shi W [61]	39	-	2	-	38	32
2006	Maruyama-Hosoi F [62]	85	52.5±19.5	2	69.4	-	46.6
2005	Santos MS [53]	33	35±16	3.5	-	51	33±12
2005	Lopez-Garcia JS [47]	14	47	2	78.5	60	24
2005	Ivekovic R [42]	4	27.8±7.8	3	100	-	12.8±1.7
2004	Shimazaki J [63]	21	43.2±19.1	2.5	-	80	15
2003	Gomes JA [46]	16	42.3±11.2	3	87.5	62	18.3±6.1

**3. Transplantation of ex vivo expanded LSC on AM**

This method of treatment is used in cases of bilateral, complete limbus injury, or when there is not enough healthy limbal tissue in the contralateral eye to collect sufficient LSCs. There are two main surgical procedures: cultivated limbal epithelial transplantation (CLET) and cultivated oral mucosal epithelial transplantation (COMET) [64]. The source of cells can be either autologous, or allogenic. The main advantage of these techniques is the small size of donor tissue (<1 mm<sup>2</sup>) [65],

while, also, presenting a low risk of damaging the donor eye. AM here serves as a carrier for cultured cells. De-epithelialized AM is preferred over the intact AM, as it better facilitates the migration of LSCs. It has also been reported that AM provides a beneficial stromal microenvironment for LSCs expansion and preservation. Furthermore, it is believed that AM protects cultured LSCs from apoptosis [66].

*Cultivation on AM*

One method of cultivation is chopping the tissue into small

fragments and subsequently placing it on the epithelium side of the AM [67]. Another method consists in obtaining single cell suspension by incubating the tissue with trypsin and then seeding the cells on AM [64, 68].

The minimal size of live limbal tissue, required to obtain enough cells for expansion and transplantation, is 0.3 mm<sup>2</sup> (0.5 mm<sup>2</sup> for cadaveric limbal tissue) [69]. For oral mucosal epithelium, a specimen of 3 mm<sup>2</sup> is required [70].

*Surgical technique*

The fibrovascular pannus is surgically debrided and the perilimbal scarring tissue is removed at least 2 mm behind the limbus. The cultivated epithelial cells, together with the AM substrate, are then placed on the cornea, with the epithelial side

facing up, and secured with sutures to the ocular surface.

*Results*

A total of 23 studies [71-93] were selected for the analysis of the outcome of CLET and COMET combined with AM substrate (Table 3). The rejection rate of CLET was relatively low, even when allogenic tissue was used, thanks to the small size of transplanted tissue [94], and the rate of success was stable even after one year [68, 71]. Similarly, the successful rate of COMET was stable two years after surgery [72]. The result of immunostaining and PCR showed that although oral mucosal epithelial cells expanded on AM became phenotypically similar to limbal and corneal epithelium, they did not undergo a veracious differentiation [73].

**Table 3**  
*Outcomes of CLET/COMET on AM substrate in patients with LSCD*

Year of publication	Author	No of eyes	Mean age	Re-epithelialization (weeks)	Stable cornea (%)	VA improvement (%)	Follow-up (months)
2017	Parihar JK [74]	25	46±6	3	88	40	12
2017	Cheng J [75]	80	42.4±13.7	2.5	-	-	26.4±13.6
2016	Scholz SL [76]	61	48.9±17.5	4	-	-	50.8±32.7
2016	Prabhasawat P [73]	20	48.2±15.5	2	75	38	31.9±12.1
2015	Ramirez BE [77]	20	51.6±14.2	1.5	-	-	36
2015	Ganger A [71]	62	14.7±10	3	82.2	42	21.4±17.8
2015	Dobrowolski D [90]	17	31.1±11.5	3	-	44	16±2.2
2014	Zakaria N [78]	18	40.7±19.4	4	72.2	-	23.7±13.3
2014	Vazirani J [79]	70	24±12.5	3	72.8	38	17.5±7
2013	Subramaniam SV [80]	40	16.8±9.3	3	-	51	33.4±29.2
2013	Sejpal K [81]	107	7.5±3.72	2.5	68.2	-	41.2±26
2013	Qi X [82]	42	38±14.7	3.5	73.8	39	17.8±3.8
2012	Prabhasawat P [83]	19	44.7±15.2	4	-	-	26.1±13.5
2012	Basu S [84]	50	20.7±11.4	3	74	55	27.6±16.8
2012	Basu S [85]	28	27.9±17.4	2	-	38	58±33.6
2012	Hirayama M [91]	16	58.4±17.7	2.5	75	-	35±17.6
2011	Sharma S [86]	50	14.5±10	4	24	-	13.8±2.9
2011	Sangwan VS [87]	200	24.1±9.9	3	64.5	59	36±19.2
2011	Satake Y [92]	40	58.5	3.5	-	75	25.5
2011	Nakamura T [72]	19	54±21	1.5	63.1	-	55±17
2010	Pauklin M [88]	44	47.4±20.1	4	-	80	28.5±14.9
2010	Meller D [89]	30	47.4±20.1	2.5	73.3	62	28.9±15.5
2006	Inatomi T [93]	15	48.4±22.3	3	-	-	20±11

**4. Transplantation of in vivo expanded LSC on AM**

This new surgical technique, called Simple Limbal Epithelial Transplantation (SLET), is usually employed in the management of unilateral LSCD. It consists in the in vivo expansion of limbal tissue pieces on AM. Because it is relatively cheap, easy to perform and requires very low amounts of donor tissue, it combines the advantages of both CLAU and CLET techniques.

*Surgical technique*

AM is secured on the ocular surface with the epithelial side up and the donor limbal tissue is then placed on the AM [55, 95]. There are, also, modified versions of SLET. Instead of placing the limbal explants on the AM, they can also be placed directly on

the cornea, using the AM to cover both the grafts and the entire ocular surface [96]. Another modification, called "sandwich technique", consists in placing the donor tissue between two layers of AM [97].

*Results*

A total of 4 [95, 98-100] studies were selected (Table 4). Although the follow-up period was relatively short (up to 18 months), SLET showed excellent results in the treatment of LSCD. Re-epithelialization was achieved in 3-4 weeks after surgery, while stable avascular cornea was reported in 80% cases at 12 months and in 76% cases at 18 months [95, 99].

**Table 4***Outcomes of SLET in patients with LSCD*

Year of publication	Author	No of eyes	Mean age	Re-epithelialization (weeks)	Stable cornea (%)	VA improvement (%)	Follow-up (months)
2017	Iyer G <sup>[98]</sup>	18	-	4	100	-	10.3±6.7
2017	Arora R <sup>[55]</sup>	10	15.2±10.8	3	100	80	6
2016	Vazirani J <sup>[99]</sup>	68	22	3	80	61	12
2016	Basu S <sup>[95]</sup>	125	-	4	76	58	18

**Conclusions**

1. The ocular surface is one of the targets of biological and bio-artificial regeneration technologies. The AM, due to its composition and unique properties, explains the special interest of researchers especially through its implications in regenerative medicine.

2. Studies on laboratory animals highlight the beneficial properties of the AM; anti-inflammatory, antimicrobial, antifibrotic and antiadhesive, analgesic and antiangiogenic. In addition, the AM is a promoter of cell differentiation and adhesion, with a low level of antigenicity through epithelial cells in the amniotic epithelium that have stem-like qualities.

3. Used in tissue engineering, the AM is an exoskeleton with a particular pattern of extracellular matrix components, having the capacity to modulate wound healing by promoting tissue reconstruction. For this reason, the AM has been employed as a substrate in numerous surgical techniques, particularly in those used for treating partial or total LSCD.

4. The approach in treating LSCD depends on the extent of the disease. Isolated AMT appears to have modest results in the long term. Although studies have consistently reported favorable outcomes of different LSC transplantation techniques combined with AMT, currently, it is unclear what is the role of AM specifically and to what extent it impacts the final result.

**Bibliography**

- Di Girolamo N. Stem cells of the human cornea. *British Medical Bulletin*. 2011;100(1):191–207. doi: 10.1093/bmb/ldr026
- Ahmad S, Figueiredo F, Lako M. Corneal epithelial stem cells: characterization, culture and transplantation. *Regen Med*. 2006;1(1):29-44. doi:10.2217/17460751.1.1.29
- Le Q, Xu J, Deng SX. The diagnosis of limbal stem cell deficiency. *Ocul Surf*. 2018;16(1):58-69. doi:10.1016/j.jtos.2017.11.002
- Kim BY, Riaz KM, Bakhtiari P, et al. Medically reversible limbal stem cell disease: clinical features and management strategies. *Ophthalmology*. 2014;121(10):2053-2058. doi:10.1016/j.ophtha.2014.04.025
- Mamede AC, Carvalho MJ, Abrantes AM, Laranjo M, Maia CJ, Botelho MF. Amniotic membrane: from structure and functions to clinical applications. *Cell Tissue Res*. 2012;349(2):447-458. doi:10.1007/s00441-012-1424-6
- Silini AR, Cargnoni A, Magatti M, Pianta S, Parolini O. The Long Path of Human Placenta, and Its Derivatives, in Regenerative Medicine. *Front Bioeng Biotechnol*. 2015 Oct 19;3:162. doi:10.3389/fbioe.2015.00162
- Tabatabaei M, Mosaffa N, Nikoo S, et al. Isolation and partial characterization of human amniotic epithelial cells: the effect of trypsin. *Avicenna J Med Biotechnol*. 2014;6(1):10-20.
- Sultana N, Chaurasia S, Ramappa M. High-resolution optical coherence tomography in a case of descemetocoele managed with amniotic membrane transplantation. *Indian J Ophthalmol*. 2018 Feb;66(2):315-317. doi:10.4103/ijo.IJO\_697\_17
- Chen EH, Tofe AJ. A literature review of the safety and biocompatibility of amnion tissue. *J Impl Adv Clin Dent*. 2010;2(3):67-75
- Mermet I, Pottier N, Sainthillier JM, et al. Use of amniotic membrane transplantation in the treatment of venous leg ulcers. *Wound Repair Regen*. 2007;15(4):459-464. doi:10.1111/j.1524-475x.2007.00252.x
- Zhu D, Muljadi R, Chan ST, et al. Evaluating the Impact of Human Amnion Epithelial Cells on Angiogenesis. *Stem Cells Int*. 2016;2016; Article ID 4565612. doi:10.1155/2016/4565612
- Fan J, Wang M, Zhong F. Improvement of Amniotic Membrane Method for the Treatment of Corneal Perforation. *Biomed Res Int*. 2016 ;2016:1693815. doi:10.1155/2016/1693815
- Liu T, Zhai H, Xu Y, et al. Amniotic membrane traps and induces apoptosis of inflammatory cells in ocular surface chemical burn. *Mol Vis*. 2012;18:2137-2146.
- Gheorghe A, Pop M, Burcea M, Serban M. New clinical application of amniotic membrane transplant for ocular surface disease. *J Med Life*. 2016;9(2):177-179.
- Goto Y, Kaneko K. Minimal model for stem cell differentiation. *Phys Rev E Stat Nonlin Soft Matter Phys*. 2013;88(3):032718.
- Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. *Stem Cell Res Ther*. 2019;10(1):68. Published 2019 Feb 26. doi:10.1186/s13287-019-1165-5
- Jirsova K, Dudakova L, Kalasova S, Vesela V, Merjava S. The OV-TL 12/30 clone of anti-cytokeratin 7 antibody as a new marker of corneal conjunctivalization in patients with limbal stem cell deficiency. *Invest Ophthalmol Vis Sci*. 2011;52(8):5892-5898. Published 2011 Jul 29. doi:10.1167/iiov.10-6748
- Eslani M, Baradaran-Rafii A, Ahmad S. Cultivated limbal and oral mucosal epithelial transplantation. *Semin Ophthalmol*. 2012;27(3-4):80-93. doi:10.3109/08820538.2012.680641
- Gheorghe A, Pop M, Mrini F, Barac R, Vargau I. Ocular surface reconstruction in limbal stem cell deficiency. *Rom J Ophthalmol*. 2016;60(1):2-5.
- Tabatabaei M, Mosaffa N, Nikoo S, et al. Isolation and partial characterization of human amniotic epithelial cells: the effect of trypsin. *Avicenna J Med Biotechnol*. 2014;6(1):10-20.
- McNairn AJ, Guash G. Epithelial transition zones: merging microenvironments, niches and cellular transformation. *Eur J Dermatol*. 2011;21:21-8.
- Brignole-Baudouin F, Liang H, Trinh L, et al. Regulation immunologique de la surface oculaire. *Surface Oculaire*. Published May 6, 2015. Available from: [https://www.em-consulte.com/em/SFO/2015/html/file\\_100012.html](https://www.em-consulte.com/em/SFO/2015/html/file_100012.html). Accessed February 15, 2020. French.

23. Eslani M, Baradaran-Rafii A, Movahedan A, Djalilian AR. The ocular surface chemical burns. *J Ophthalmol.* 2014;2014; Article ID 196827. doi:10.1155/2014/196827
24. Lin A, Patel N, Yoo D, DeMartelaere S, Bouchard C. Management of ocular conditions in the burn unit: thermal and chemical burns and Stevens-Johnson syndrome/toxic epidermal necrolysis. *J Burn Care Res.* 2011 Sep-Oct;32(5):547-560. doi:10.1097/BCR.0b013e31822b0f29
25. Liu J, Sheha H, Fu Y, Liang L & Tseng SC. Update on amniotic membrane transplantation, *Expert Rev Ophthalmol.* 2010 Oct; 5(5):645-661. doi:10.1586/eop.10.63
26. Saghizadeh M, Winkler MA, Kramerov AA, et al. A simple alkaline method for decellularizing human amniotic membrane for cell culture. *PLoS One.* 2013;8(11):e79632. Published 2013 Nov 13. doi:10.1371/journal.pone.0079632
27. Jirsova K, Jones GLA. Amniotic membrane in ophthalmology: properties, preparation, storage and indications for grafting—a review. *Cell Tissue Bank.* 2017;18(2):193-204. doi:10.1007/s10561-017-9618-5
28. Singh R, Gupta P, Kumar P, Kumar A, Chacharkar MP. Properties of Air Dried Radiation Processed Amniotic Membranes under Different Storage Conditions. *Cell Tissue Bank.* 2003;4(2-4):95-100. doi:10.1023/B:CATB.0000007030.72031.12
29. Gajiwala K, Gajiwala AL. Evaluation of lyophilised, gamma-irradiated amnion as a biological dressing. *Cell Tissue Bank.* 2004;5(2):73-80. doi:10.1023/B:CATB.0000034076.16744.4b
30. European Committee on Organ Transplantation. Guide to the quality and safety of tissues and cells for human application. Specific ocular tissue requirements. EDQM, 2nd Edition, 2015. (CD-P-T0) Chapter 13. 221-233.
31. Malhotra C, Jain AK. Human amniotic membrane transplantation: Different modalities of its use in ophthalmology. *World J Transplant.* 2014;4(2):111-121. doi:10.5500/wjt.v4.i2.111
32. Meller D, Pauklin M, Thomasen H, Westekemper H, Steuhl KP. Amniotic membrane transplantation in the human eye. *Dtsch Arztebl Int.* 2011;108(14):243-248. doi:10.3238/arztebl.2011.0243
33. Zakaria N, Koppen C, Van Tendeloo V, Berneman Z, Hopkinson A, Tassignon MJ. Standardized limbal epithelial stem cell graft generation and transplantation. *Tissue Eng Part C Methods.* 2010;16(5):921-927. doi:10.1089/ten.TEC.2009.0634
34. Gomes JA, Geraldes Monteiro B, Melo GB, et al. Corneal reconstruction with tissue-engineered cell sheets composed of human immature dental pulp stem cells. *Invest Ophthalmol Vis Sci.* 2010;51(3):1408-1414. doi:10.1167/iovs.09-4029
35. Gubar OS, Rodnichenko AE, Vasyliov RG, Zlatska AV, Zubov DO. Postnatal extra-embryonic tissues as a source of multiple cell types for regenerative medicine applications. *Exp Oncol.* 2017;39(3):186-190.
36. Sharma N, Thenarasun SA, Kaur M, et al. Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson Syndrome: A Randomized Control Trial. *Ophthalmology.* 2016;123(3):484-491. doi:10.1016/j.optha.2015.10.027
37. Shupe AT, Cheng AMS. Case Report: Use of Self-retained Cryopreserved Amniotic Membrane in the Treatment of Acute Chemical Ocular Burn. *Optom Vis Sci.* 2017;94(11):1062-1065. doi:10.1097/OPX.0000000000001132
38. Konomi K, Satake Y, Shimmura S, Tsubota K, Shimazaki J. Long-term results of amniotic membrane transplantation for partial limbal deficiency. *Cornea.* 2013;32(8):1110-1115. doi:10.1097/ICO.0b013e31828d06d2
39. Meesuk L, Tantrawatpan C, Kheolamai P, Manochantr S. The immunosuppressive capacity of human mesenchymal stromal cells derived from amnion and bone marrow. *Biochem Biophys Rep.* 2016;8:34-40. Published 2016 Aug 3. doi:10.1016/j.bbrep.2016.07.019
40. Anderson DF, Ellies P, Pires RT, Tseng SC. Amniotic membrane transplantation for partial limbal stem cell deficiency. *Br J Ophthalmol.* 2001;85(5):567-575. doi:10.1136/bjo.85.5.567
41. Chugh JP, Jain P, Sen R. Comparative analysis of fresh and dry preserved amniotic membrane transplantation in partial limbal stem cell deficiency. *Int Ophthalmol.* 2015 Jun;35(3):347-355. doi: 10.1007/s10792-014-9954-4
42. Ivekovic R, Tedeschi-Reiner E, Novak-Laus K, Andrijevic-Derk B, Cima I, Mandic Z. Limbal graft and/or amniotic membrane transplantation in the treatment of ocular burns. *Ophthalmologica.* 2005;219(5):297-302. doi:10.1159/000086115
43. Westekemper H, Figueiredo FC, Siah WF, Wagner N, Steuhl KP, Meller D. Clinical outcomes of amniotic membrane transplantation in the management of acute ocular chemical injury. *Br J Ophthalmol.* 2017;101(2):103-107. doi:10.1136/bjophthalmol-2015-308037
44. Goktas SE, Katircioglu Y, Celik T, Ornek F. Surgical amniotic membrane transplantation after conjunctival and limbal tumor excision. *Arq Bras Oftalmol.* 2017;80(4):242-246. doi:10.5935/0004-2749.20170059
45. Sharma N, Kaur M, Agarwal T, Sangwan VS, Vajpayee RB. Treatment of acute ocular chemical burns. *Surv Ophthalmol.* 2018;63(2):214-235. doi:10.1016/j.survophthal.2017.09.005
46. Gomes JA, dos Santos MS, Cunha MC, Mascaro VL, Barros Jde N, de Sousa LB. Amniotic membrane transplantation for partial and total limbal stem cell deficiency secondary to chemical burn. *Ophthalmology.* 2003;110(3):466-473. doi:10.1016/s0161-6420(02)01888-2
47. López-García JS, Rivas L, García-Lozano I. Trasplante de membrana amniótica en el tratamiento de la insuficiencia limbal moderada de pacientes con aniridia congénita [Moderate limbal deficiency in patients with congenital aniridia treated with amniotic membrane transplantation]. *Arch Soc Esp Oftalmol.* 2005;80(9):517-523. Spanish. doi:10.4321/s0365-66912005000900005
48. Kheirkhah A, Casas V, Raju VK, Tseng SC. Sutureless amniotic membrane transplantation for partial limbal stem cell deficiency. *Am J Ophthalmol.* 2008;145(5):787-794. doi:10.1016/j.ajo.2008.01.009
49. Daya SM. Conjunctival-limbal autograft. *Curr Opin Ophthalmol.* 2017;28(4):370-376. doi:10.1097/ICU.0000000000000385
50. Gheorghe A, Pop M, Mrini F, Barac R, Vargau I. Ocular surface reconstruction in limbal stem cell deficiency. *Rom J Ophthalmol.* 2016;60(1):2-5.
51. Barreiro TP, Santos MS, Vieira AC, et al. Comparative study of conjunctival limbal transplantation not associated with the use of amniotic membrane transplantation for treatment of total limbal deficiency secondary to chemical injury. *Cornea.* 2014 Jul;33(7):716-720. doi: 10.1097/ico.0000000000000139
52. López-García JS, Rivas L, García-Lozano I. Tratamiento de la insuficiencia limbal grave mediante cirugía combinada de trasplante de limbo y trasplante de membrana amniótica [Severe limbal deficiency treated by combined limbal allograft and amniotic membrane transplantation]. *Arch Soc Esp Oftalmol.* 2005;80(9):405-412. Spanish. doi:10.4321/s0365-66912005000700005
53. Santos MS, Gomes JA, Hofling-Lima AL, Rizzo LV, Romano AC, Belfort R Jr. Survival analysis of conjunctival limbal grafts and amniotic membrane transplantation in eyes with total limbal stem cell deficiency. *Am J Ophthalmol.* 2005;140(2):223-230. doi:10.1016/j.ajo.2005.03.022
54. Scocco C, Kwitko S, Rymer S, Marinho D, Bocaccio F, Lindenmeyer R. HLA-matched living-related conjunctival limbal allograft for bilateral ocular surface disorders: long-



- term results. *Arq Bras Oftalmol.* 2008;71(6):781-787. doi:10.1590/s0004-27492008000600003
55. Arora R, Dokania P, Manudhane A, Goyal JL. Preliminary results from the comparison of simple limbal epithelial transplantation with conjunctival limbal autologous transplantation in severe unilateral chronic ocular burns. *Indian J Ophthalmol.* 2017;65(1):35-40. doi:10.4103/0301-4738.202312
  56. Baradaran-Rafii A, Eslani M, Jamali H, Karimian F, Taylor UA, Djalilian AR. Postoperative complications of conjunctival limbal autograft surgery. *Cornea.* 2012;31(8):893-899. doi:10.1097/ICO.0b013e31823f095d
  57. Miri A, Al-Deiri B, Dua HS. Long-term outcomes of autolimbic and allolimbic transplants. *Ophthalmology.* 2010;117(6):1207-1213. doi:10.1016/j.ophtha.2009.10.028
  58. Moreira PB, Magalhães RS, Pereira NC, Oliveira LA, Sousa LB. Limbal transplantation at a tertiary hospital in Brazil: a retrospective study. *Arq Bras Oftalmol.* 2015;78(4):207-211. doi:10.5935/0004-2749.20150054
  59. Eberwein P, Böhringer D, Schwartzkopf J, Birnbaum F, Reinhard T. Allogenic limbo-keratoplasty with conjunctivoplasty, mitomycin C, and amniotic membrane for bilateral limbal stem cell deficiency. *Ophthalmology.* 2012;119(5):930-937. doi:10.1016/j.ophtha.2011.10.039
  60. Han ES, Wee WR, Lee JH, Kim MK. Long-term outcome and prognostic factor analysis for keratolimbal allografts. *Graefes Arch Clin Exp Ophthalmol.* 2011;249(11):1697-1704. doi:10.1007/s00417-011-1760-3
  61. Shi W, Gao H, Wang T, Xie L. Combined penetrating keratoplasty and keratolimbal allograft transplantation in comparison with corneoscleral transplantation in the treatment of severe eye burns. *Clin Exp Ophthalmol.* 2008;36(6):501-507. doi:10.1111/j.1442-9071.2008.01802.x
  62. Maruyama-Hosoi F, Shimazaki J, Shimmura S, Tsubota K. Changes observed in keratolimbal allograft. *Cornea.* 2006;25(4):377-382. doi:10.1097/01.ico.0000176608.65708.27
  63. Shimazaki J, Shimmura S, Tsubota K. Donor source affects the outcome of ocular surface reconstruction in chemical or thermal burns of the cornea. *Ophthalmology.* 2004;111(1):38-44. doi:10.1016/j.ophtha.2003.02.003
  64. Gopakumar V, Agarwal S, Srinivasan B, Krishnakumar S, Krishnan UM, Iyer G. Clinical Outcome of Autologous Cultivated Oral Mucosal Epithelial Transplantation in Ocular Surface Reconstruction. *Cornea.* 2019;38(10):1273-1279. doi:10.1097/ICO.0000000000002082
  65. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. *N Engl J Med.* 2010;363(2):147-155. doi:10.1056/NEJMoa0905955
  66. Shahdadfar A, Haug K, Pathak M, et al. Ex vivo expanded autologous limbal epithelial cells on amniotic membrane using a culture medium with human serum as single supplement. *Exp Eye Res.* 2012;97(1):1-9. doi:10.1016/j.exer.2012.01.013
  67. Sabater AL, Perez VL. Amniotic membrane use for management of corneal limbal stem cell deficiency. *Curr Opin Ophthalmol.* 2017;28(4):363-369. doi:10.1097/ICU.0000000000000386
  68. Rama P, Ferrari G, Pellegrini G. Cultivated limbal epithelial transplantation. *Curr Opin Ophthalmol.* 2017;28(4):387-389. doi:10.1097/ICU.0000000000000382
  69. Kethiri AR, Basu S, Shukla S, Sangwan VS, Singh V. Optimizing the role of limbal explant size and source in determining the outcomes of limbal transplantation: An in vitro study. *PLoS One.* 2017;12(9):e0185623. Published 2017 Sep 28. doi:10.1371/journal.pone.0185623
  70. Sotozono C, Inatomi T, Nakamura T, et al. Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. *Acta Ophthalmol.* 2014;92(6):e447-e453. doi:10.1111/aos.12397
  71. Ganger A, Vanathi M, Mohanty S, Tandon R. Long-Term Outcomes of Cultivated Limbal Epithelial Transplantation: Evaluation and Comparison of Results in Children and Adults. *Biomed Res Int.* 2015;2015; Article ID 480983. doi:10.1155/2015/480983
  72. Nakamura T, Takeda K, Inatomi T, Sotozono C, Kinoshita S. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. *Br J Ophthalmol.* 2011;95(7):942-946. doi:10.1136/bjo.2010.188714
  73. Prabhasawat P, Ekpo P, Uiprasertkul M, et al. Long-term result of autologous cultivated oral mucosal epithelial transplantation for severe ocular surface disease. *Cell Tissue Bank.* 2016;17(3):491-503. doi:10.1007/s10561-016-9575-4
  74. Parihar JKS, Parihar AS, Jain VK, Kaushik J, Nath P. Allogenic cultivated limbal stem cell transplantation versus cadaveric keratolimbal allograft in ocular surface disorder: 1-year outcome. *Int Ophthalmol.* 2017;37(6):1323-1331. doi:10.1007/s10792-016-0415-0
  75. Cheng J, Zhai H, Wang J, Duan H, Zhou Q. Long-term outcome of allogeneic cultivated limbal epithelial transplantation for symblepharon caused by severe ocular burns. *BMC Ophthalmol.* 2017;17(1):8. Published 2017 Jan 31. doi:10.1186/s12886-017-0403-9
  76. Scholz SL, Thomassen H, Hestermann K, Dekowski D, Steuhl KP, Meller D. Langzeitergebnisse zur autologen Transplantation von ex vivo kultiviertem Limbusepithel bei limbaler Stammzellinsuffizienz [Long-term results of autologous transplantation of limbal epithelium cultivated ex vivo for limbal stem cell deficiency]. *Ophthalmologie.* 2016;113(4):321-329. German. doi:10.1007/s00347-015-0110-y
  77. Ramírez BE, Sánchez A, Herreras JM, et al. Stem Cell Therapy for Corneal Epithelium Regeneration following Good Manufacturing and Clinical Procedures. *Biomed Res Int.* 2015;2015:408495. doi:10.1155/2015/408495
  78. Zakaria N, Possemiers T, Dhubhghaill SN, et al. Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation. *J Transl Med.* 2014;12:58. Published 2014 Mar 3. doi:10.1186/1479-5876-12-58.
  79. Vazirani J, Basu S, Kenia H, et al. Unilateral partial limbal stem cell deficiency: contralateral versus ipsilateral autologous cultivated limbal epithelial transplantation. *Am J Ophthalmol.* 2014;157(3):584-590. doi:10.1016/j.ajo.2013.11.011
  80. Subramaniam SV, Sejpal K, Fatima A, Gaddipati S, Vemuganti GK, Sangwan VS. Coculture of autologous limbal and conjunctival epithelial cells to treat severe ocular surface disorders: long-term survival analysis. *Indian J Ophthalmol.* 2013;61(5):202-207. doi:10.4103/0301-4738.99840
  81. Sejpal K, Ali MH, Maddileti S, et al. Cultivated limbal epithelial transplantation in children with ocular surface burns. *JAMA Ophthalmol.* 2013;131(6):731-736. doi:10.1001/jamaophthalmol.2013.2308
  82. Qi X, Xie L, Cheng J, Zhai H, Zhou Q. Characteristics of immune rejection after allogeneic cultivated limbal epithelial transplantation. *Ophthalmology.* 2013;120(5):931-936. doi:10.1016/j.ophtha.2012.11.001
  83. Prabhasawat P, Ekpo P, Uiprasertkul M, Chotikavanich S, Tesavibul N. Efficacy of cultivated corneal epithelial stem cells for ocular surface reconstruction. *Clin Ophthalmol.* 2012;6:1483-1492. doi:10.2147/OPTH.S33951
  84. Basu S, Ali H, Sangwan VS. Clinical outcomes of repeat autologous cultivated limbal epithelial transplantation for ocular surface burns. *Am J Ophthalmol.* 2012;153(4):643-650. doi:10.1016/j.ajo.2011.09.016
  85. Basu S, Fernandez MM, Das S, Gaddipati S, Vemuganti GK, Sangwan VS. Clinical outcomes of xeno-free allogeneic cultivated limbal epithelial transplantation for bilateral

- limbal stem cell deficiency. *Br J Ophthalmol.* 2012;96(12):1504-1509. doi:10.1136/bjophthalmol-2012-301869
86. Sharma S, Tandon R, Mohanty S, et al. Culture of corneal limbal epithelial stem cells: experience from benchtop to bedside in a tertiary care hospital in India. *Cornea.* 2011;30(11):1223-1232. doi:10.1097/ICO.0b013e3181d8c81f1
87. Sangwan VS, Basu S, Vemuganti GK, et al. Clinical outcomes of xeno-free autologous cultivated limbal epithelial transplantation: a 10-year study. *Br J Ophthalmol.* 2011;95(11):1525-1529. doi:10.1136/bjophthalmol-2011-300352
88. Pauklin M, Fuchsluger TA, Westekemper H, Steuhl KP, Meller D. Midterm results of cultivated autologous and allogeneic limbal epithelial transplantation in limbal stem cell deficiency. *Dev Ophthalmol.* 2010;45:57-70. doi:10.1159/000315020
89. Meller D, Pauklin M, Westekemper H, Steuhl KP. Autologe Transplantation von kultiviertem Limbusepithel [Autologous transplantation of cultivated limbal epithelium]. *Ophthalmologe.* 2010;107(12):1133-1138. German. doi:10.1007/s00347-010-2205-9
90. Dobrowolski D, Orzechowska-Wylegala B, Wowra B, et al. Cultivated Oral Mucosa Epithelium in Ocular Surface Reconstruction in Aniridia Patients. *Biomed Res Int.* 2015;2015:281870. doi:10.1155/2015/281870
91. Hirayama M, Satake Y, Higa K, Yamaguchi T, Shimazaki J. Transplantation of cultivated oral mucosal epithelium prepared in fibrin-coated culture dishes. *Invest Ophthalmol Vis Sci.* 2012;53(3):1602-1609. Published 2012 Mar 21. doi:10.1167/iovs.11-7847
92. Satake Y, Higa K, Tsubota K, Shimazaki J. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. *Ophthalmology.* 2011;118(8):1524-1530. doi:10.1016/j.ophtha.2011.01.039
93. Inatomi T, Nakamura T, Koizumi N, Sotozono C, Yokoi N, Kinoshita S. Midterm results on ocular surface reconstruction using cultivated autologous oral mucosal epithelial transplantation. *Am J Ophthalmol.* 2006;141(2):267-275. doi:10.1016/j.ajo.2005.09.003
94. Shortt AJ, Tuft SJ, Daniels JT. Corneal stem cells in the eye clinic. *Br Med Bull.* 2011;100:209-225. doi:10.1093/bmb/ldr041
95. Basu S, Sureka SP, Shanbhag SS, Kethiri AR, Singh V, Sangwan VS. Simple Limbal Epithelial Transplantation: Long-Term Clinical Outcomes in 125 Cases of Unilateral Chronic Ocular Surface Burns. *Ophthalmology.* 2016;123(5):1000-1010. doi:10.1016/j.ophtha.2015.12.042
96. Vasquez-Perez A, Nanavaty MA. Modified Allogenic Simple Limbal Epithelial Transplantation Followed by Keratoplasty as Treatment for Total Limbal Stem Cell Deficiency. *Ocul Immunol Inflamm.* 2018;26(8):1189-1191. doi:10.1080/09273948.2017.1332229
97. Amescua G, Atallah M, Nikpoor N, Galor A, Perez VL. Modified simple limbal epithelial transplantation using cryopreserved amniotic membrane for unilateral limbal stem cell deficiency. *Am J Ophthalmol.* 2014;158(3):469-75.e2. doi:10.1016/j.ajo.2014.06.002
98. Iyer G, Srinivasan B, Agarwal S, Tarigopula A. Outcome of allo simple limbal epithelial transplantation (alloSLET) in the early stage of ocular chemical injury. *Br J Ophthalmol.* 2017;101(6):828-833. doi:10.1136/bjophthalmol-2016-309045
99. Vazirani J, Ali MH, Sharma N, et al. Autologous simple limbal epithelial transplantation for unilateral limbal stem cell deficiency: multicentre results. *Br J Ophthalmol.* 2016;100(10):1416-1420. doi:10.1136/bjophthalmol-2015-307348
100. Tsai RJ, Li LM, Chen JK. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells. *N Engl J Med.* 2000;343(2):86-93. doi: 10.1056/NEJM200007133430202

---

Received – 09.08.2020, accepted for publication – 20.09.2020

**Corresponding author:** Vitalie Procopciuc, email: provit88@gmail.com

**Conflict of interest Statement:** The authors report no conflicts of interest in this work.

**Funding Statement:** This research was supported in part by the Ministry of Education, Culture and Research of the Republic of Moldova, under the Grant #20.80009.5007.20, and the Laboratory of Tissue Engineering and Cell Cultures from University of Medicine and Pharmacy "Nicolae Testemițanu", Chișinău, Republic of Moldova. The funders had no role in study design, data collection and analysis, decision on publishing or preparation of the manuscript.

**Citation:** Procopciuc V., Mihaluța V., Ignatov O., Cușnir V., Nacu V. Efficiency of amniotic membrane transplantation in the management of limbal stem cell deficiency. *Arta Medica.* 2020;76(3):100-109.